Cited by 530NF-κB Signaling PathwaysCytokine Signaling Pathways and InteractionsInflammatory mediators and NSAID effects

Signaling Pathways in Inflammation and Anti-inflammatory Therapies.

Yeung, Yiu To, Aziz, Faisal, Guerrero-Castilla, Angelica, Arguelles, Sandro·2018·Current Pharmaceutical Design

Abstract

During the past decade, an abundance of new evidence highlighted the importance of inflammation in the development of chronic pathologies such as neurodegeneration, cancer, diabetes, cardiovascular disease and inflammatory bowel disease. However, most of the current therapies do not address the underlying problem and better therapies are urgently needed. A growing number of researchers have discovered various signaling pathways that are associated with the initiation and progression of inflammation. Among different pathways, we will focus on three classical inflammatory pathways: p38 MAPK, IL-6/JAK/STAT3 and PI3K; and a non-classical inflammatory pathway, the Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as FoxO1/3, TNFα, IL-6, COX2, HIF-1α, AP-1, JAK and STAT. In this review, the molecular mechanisms, associated pathologies and selected drugs (both preclinical and clinical) of these signaling pathways will be summarized. Finally, limitations and potential risks of anti-inflammatory drugs will also be discussed.

Integrity signals

Registry

Crossref · 10.2174/1381612824666180327165604

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cited by

Sorted by citations

Authors
Yeung, Y. T., Aziz, F., Guerrero-Castilla, A., & Arguelles, S.
Affiliations
  • China-US (Henan) Hormel Cancer Institute (CN)
  • Quimica y Farmacia, Facultad de Ciencias de la Salud, Universidad Arturo Prat, Casilla 121, Iquique 1100000, Chile
  • Department of Physiology, Faculty of Pharmacy, University of Seville, Seville, Spain
Venue
Current Pharmaceutical Design
Published
2018-07-13
Volume
24
Issue
14
Pages
1449-1484
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2795279419
Cited by
530
References
0
Citations by year
2026: 63 · 2025: 96 · 2024: 98 · 2023: 80 · 2022: 88 · 2021: 62 · 2020: 32 · 2019: 7 · 2018: 4
FWCI
7.91
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
Keywords
inflammation, signaling pathways, anti-inflammatory agents, p38 MAPK, phosphatidylinositol 3-kinase, Hippo signaling pathway, TNF-α, cyclooxygenase-2, HIF-1α, AP-1, chronic disease, adverse drug reactions
MeSH terms
Animals, Anti-Inflammatory Agents, Humans, Inflammation, Signal Transduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review